Spots Global Cancer Trial Database for ovarian cancer
Every month we try and update this database with for ovarian cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer | NCT02043158 | Ovarian Cancer | Questionnaire Interview | 18 Years - | M.D. Anderson Cancer Center | |
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | NCT00667641 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Prostate Cancer Unspecified Adu... | bortezomib paclitaxel | 18 Years - | Rutgers, The State University of New Jersey | |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | NCT03205176 | Malignant Solid... Lymphoma Ovarian Cancer Breast Cancer Pancreatic Canc... Prostate Cancer | AZD5153 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT06161025 | Solid Cancer | R-DXd Gemcitabine Paclitaxel Topotecan PLD | 18 Years - | Daiichi Sankyo | |
| MR-HIFU for Recurrent Gynaecological Cancer | NCT02714621 | Cervical Cancer Endometrial Can... Uterine Cancer Ovarian Cancer Vaginal Cancer Vulvar Cancer | Magnetic Resona... | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01767675 | Ovarian Cancer Fallopian Tubes... Peritoneal Canc... | Secondary Cytor... Carboplatin Hyp... platinum-based ... platinum-based ... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | NCT00005046 | Ovarian Cancer Primary Periton... | chemotherapy paclitaxel | 21 Years - | GOG Foundation | |
| Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | NCT00569673 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim pegfilgrastim docetaxel trabectedin | 18 Years - 120 Years | GOG Foundation | |
| Prevention of Ovarian Cancer in Women Participating in Mammography | NCT01851109 | Epithelial Ovar... | genetic counsel... | 35 Years - | Fred Hutchinson Cancer Center | |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | NCT01493505 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | AMG 386 Paclitaxel AMG 386 Placebo Carboplatin | 18 Years - | Amgen | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer | NCT03519230 | Ovarian Cancer | Pamiparib capsu... Placebo capsule | 18 Years - | BeiGene | |
| A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer | NCT03602859 | Ovarian Neoplas... Ovarian, Fallop... | Niraparib Dostarlimab (TS... Standard of car... Dostarlimab-Pla... Niraparib-Place... | 18 Years - | Tesaro, Inc. | |
| Ovarian Cancer Patient-Centered Decision Aid | NCT02259699 | Stage III Ovari... | Decision Aid | 21 Years - | University of California, Irvine | |
| Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk | NCT00735150 | Breast Cancer Ovarian Cancer | questionnaire, ... | 18 Years - 39 Years | Memorial Sloan Kettering Cancer Center | |
| Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation | NCT02664389 | Breast Cancer Ovarian Cancer Colorectal Canc... Pediatric Cance... Multiple Primar... | Genetic analysi... | - | University Hospital, Rouen | |
| A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers | NCT02824328 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Uterine Endomet... | 18 Years - | Duke University | ||
| A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | NCT01685255 | Ovarian Cancer Genitourinary (... | Epacadostat tamoxifen | 18 Years - | Incyte Corporation | |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | NCT03940196 | Ovarian Cancer | NovoTTF-100L(O) Paclitaxel | 18 Years - | NovoCure Ltd. | |
| Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients | NCT00478452 | Ovarian Cancer Fallopian Tube ... Primary Periton... | DC-Ova DC Ova with Cyc... | 18 Years - | University of Pennsylvania | |
| The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies | NCT00726635 | Cancer of Cervi... Ovarian Cancer Cancer of Endom... | Cognitive inter... Control group psycho-physiolo... | 18 Years - 70 Years | Rabin Medical Center | |
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | NCT00471432 | Bladder Cancer Breast Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adu... | custirsen sodiu... docetaxel pharmacological... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Integrated Care Pathway in Oncology (PASSION) | NCT04235556 | Colon Cancer Gastric Cancer Pancreatic Canc... Thoracic Neopla... Breast Cancer Ovarian Cancer Bladder Cancer Prostate Cancer | Care pathway un... | 18 Years - 80 Years | Assistance Publique - Hôpitaux de Paris | |
| Cost Utility of Radical Surgery in Ovarian Cancer | NCT02854215 | Ovarian Cancer | Collection of a... | 18 Years - | Institut Claudius Regaud | |
| Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors | NCT00006036 | Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | cisplatin lurtotecan lipo... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery | NCT03519165 | Ovarian Cancer | EV1000(FloTrac ... | 18 Years - 65 Years | Tata Medical Center | |
| Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) | NCT02537444 | Ovarian Cancer | Acalabrutinib acalabrutinib a... | 18 Years - | Acerta Pharma BV | |
| CA-125 in Screening Patients at High Risk for Ovarian Cancer | NCT00080639 | Ovarian Cancer | physiologic tes... study of high r... | 30 Years - | University of Alabama at Birmingham | |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer | NCT01166737 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | Tumor Debulking... | 18 Years - | AGO Study Group | |
| Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer | NCT00170573 | Ovarian Cancer | Caelyx | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| CONTIGO - Informing Latinas About HBOC Risk | NCT05130606 | Hereditary Brea... | Culturally Targ... FORCE Fact Shee... | 18 Years - | Georgetown University | |
| Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer | NCT03936270 | Ovarian Cancer | Palbociclib 125... Letrozole 2.5mg | 18 Years - | Latin American Cooperative Oncology Group | |
| Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | NCT00083928 | Ovarian Cancer Primary Periton... | Å6 subcutaneous... | 18 Years - | Ångstrom Pharmaceuticals | |
| Genetically-informed Therapies for Patients With Metastatic Cancer | NCT02000739 | Metastatic Canc... | Genetically Inf... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | NCT04068896 | Pancreatic Canc... Metastatic Cast... Bladder Cancer Melanoma Non-small Cell ... Colorectal Canc... Gastric Cancer Esophageal Canc... Ovarian Cancer Head Neck Squam... Prostate Cancer | NGM120 NGM120 NGM120 NGM120 NGM120 NGM120 Placebo | 18 Years - | NGM Biopharmaceuticals, Inc | |
| Clinical Significance of Germline BRCA Mutations | NCT00579488 | Breast Cancer Ovarian Cancer | 18 Years - | Memorial Sloan Kettering Cancer Center | ||
| Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | NCT04918186 | Ovarian Cancer | Durvalumab BA3011 BA3021 To be determine... | 18 Years - | Canadian Cancer Trials Group | |
| Preference Study With Elderly Patients Recurrent Ovarian Cancer | NCT00170690 | Ovarian Cancer | Treosulfan Treosulfan | 70 Years - | North Eastern German Society of Gynaecological Oncology | |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | NCT03641287 | Ovarian Cancer Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian Adenoca... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Primary Periton... Primary Periton... | Exercise Counse... Aerobic Exercis... Physiological S... Quality-of-Life... Questionnaire A... Best Practice | 18 Years - | University of Washington | |
| Assessment of Paclitaxel-Induced Neuropathy | NCT01953159 | Cancer Breast Cancer Ovarian Cancer | Blood Collectio... Patient Questio... | 18 Years - | University of Chicago | |
| Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer | NCT03632798 | Recurrent Ovari... | ChemoID assay Chemotherapy | 18 Years - | Cordgenics, LLC | |
| Genetically-informed Therapies for Patients With Metastatic Cancer | NCT02000739 | Metastatic Canc... | Genetically Inf... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Evaluating Tools for Health Promotion and Disease Prevention | NCT00164658 | Coronary Heart ... Stroke Diabetes Breast Cancer Ovarian Cancer Colorectal Canc... | Familial risk a... | 35 Years - 65 Years | Centers for Disease Control and Prevention | |
| Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer | NCT05300828 | Ovarian Cancer | Genexl PM | 18 Years - | Seoul National University Hospital | |
| A Phase 1b Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | NCT06430541 | Breast Cancer Ovarian Cancer | Psilocybin | 21 Years - | University of Colorado, Denver | |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | NCT00601406 | Breast Cancer Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... Prostate Cancer Sarcoma Vaginal Cancer Vulvar Cancer | gene expression... gene rearrangem... polymorphism an... laboratory biom... radiation thera... | - | National Cancer Institute (NCI) | |
| CT-2106 for the Second Line Treatment of Ovarian Cancer | NCT00291837 | Ovarian Cancer | CT-2106 | 18 Years - | CTI BioPharma | |
| Chemotherapy Supported by Autologous Hematopoietic Stem Cells | NCT05401162 | Ovarian Cancer | Autologous bloo... | 18 Years - 60 Years | Chongqing University Cancer Hospital | |
| Yoga Practice for Breast or Ovarian Cancer Patients | NCT02305498 | Ovarian Cancer Breast Cancer | Vigorous yoga p... Restorative (ge... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer | NCT00489359 | Ovarian Cancer Primary Periton... | Pemetrexed - Ph... Carboplatin - P... Pemetrexed - Ph... Carboplatin - P... | 18 Years - | Eli Lilly and Company | |
| Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | NCT01238770 | Epithelial Ovar... | Pazopanib | 18 Years - | University Hospital Heidelberg | |
| Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | NCT00964626 | Ovarian Cancer | cisplatin paclitaxel | 18 Years - 72 Years | National Cancer Institute (NCI) | |
| Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | NCT03806049 | Ovarian Cancer | Niraparib Bevacizumab TSR042 Carboplatin Paclitaxel | 18 Years - 100 Years | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125 | NCT03004391 | Ovarian Cancer | 18 Years - | Vejle Hospital | ||
| MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer | NCT03916679 | Ovarian Cancer | anti-MESO CAR-T... | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | NCT05585281 | Ovarian Cancer | Fluzoparib QL1101 | 18 Years - 70 Years | Liaoning Tumor Hospital & Institute | |
| Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | NCT02014337 | Breast Cancer Ovarian Epithel... Sarcoma Non-small Cell ... Carcinoma, Tran... Prostate Cancer Prostatic Neopl... | Mifepristone an... | 18 Years - | Corcept Therapeutics | |
| A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | NCT00001426 | Ovarian Neoplas... | Cyclophosphamid... Paclitaxel Cisplatin G-CSF | - | National Institutes of Health Clinical Center (CC) | |
| Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer | NCT00460200 | Depression Fatigue Ovarian Cancer Psychosocial Ef... Sleep Disorders | polymorphism an... laboratory biom... physiologic tes... questionnaire a... conventional su... fatigue assessm... psychosocial as... | 18 Years - 55 Years | Jonsson Comprehensive Cancer Center | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | NCT02867956 | Ovarian Cancer | Apatinib Etoposide | 18 Years - 70 Years | Sun Yat-sen University | |
| A Survivorship Care Plan for Gynaecological Cancer Patients | NCT01582906 | Adenocarcinoma ... Cervical Cancer Endometrial Can... Esophageal Canc... Fallopian Tube ... Gastric Cancer Ovarian Cancer Sarcoma Vaginal Cancer Vulvar Cancer | 18 Years - 60 Years | Royal Marsden NHS Foundation Trust | ||
| Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00112957 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | rV-NY-ESO-1 vac... rF-NY-ESO-1 vac... | 18 Years - | Ludwig Institute for Cancer Research | |
| Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients | NCT05529303 | Cervix Cancer Uterine Cancer Ovarian Cancer Endometrial Can... Vulva Cancer Grief Femininity | Such as art the... | 18 Years - 65 Years | Afyonkarahisar Health Sciences University | |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | NCT06161272 | Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ... | Fluzoparib Fluzoparib+Apat... | 18 Years - 75 Years | Guangxi Medical University | |
| Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients | NCT04227522 | Ovarian Cancer Fallopian Tube ... Primary Periton... Clear Cell Carc... | Rucaparib Placebos | 18 Years - | North Eastern German Society of Gynaecological Oncology | |
| Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention | NCT02287519 | Ovarian Cancer | Group Session Telephone Coach... Webinar | 18 Years - | Dana-Farber Cancer Institute | |
| Doppler Ultrasound and CT Versus Laparoscopy in Assessment of Ovarian Malignancy | NCT06109545 | Ovarian Cancer | Laparoscopy | 18 Years - 75 Years | Mansoura University | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust | |
| Patients Derived Organoids in Ovarian Cancer | NCT06085404 | Ovarian Cancer | Blood sample | 18 Years - 80 Years | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | NCT00635193 | Ovarian Cancer,... | M200 (Volocixim... Liposomal Doxor... M200 (Volocixim... M200 (Volocixim... | 18 Years - | AbbVie | |
| Long Term Survivors in Ovarian Cancer | NCT03128294 | Ovarian Cancer | Retrospective, ... | - | University Medical Center Groningen | |
| Open Label Immunotherapy Trial for Ovarian Cancer | NCT03556566 | Ovarian Cancer | Tableted vaccin... | 18 Years - 65 Years | Immunitor LLC | |
| Hyperpolarized 13C MRI for Cancer Immunotherapy | NCT05805358 | Gynecologic Can... Cervical Cancer Endometrial Can... Ovarian Cancer | Hyperpolarized ... | 20 Years - | Chang Gung Memorial Hospital | |
| HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China | NCT06238284 | Cervical Cancer Endometrial Can... Ovarian Cancer HER2 Expression | no intervention | 18 Years - 75 Years | Chongqing University Cancer Hospital | |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00550784 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim cisplatin cyclophosphamid... melphalan paclitaxel topotecan hydro... TdT-mediated dU... gene expression... immunohistochem... pharmacological... peripheral bloo... | - 60 Years | City of Hope Medical Center | |
| Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer | NCT00337233 | Breast Cancer Fatigue Ovarian Cancer Psychosocial Ef... | yoga therapy | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | NCT02575651 | Advanced Solid ... | Fluzoparib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | NCT05185947 | Gynecologic Can... Gynecologic Neo... Peritoneal Carc... Peritoneal Neop... Ovarian Cancer Ovarian Neoplas... Colorectal Canc... Colorectal Neop... Appendiceal Can... Appendiceal Neo... | Paclitaxel Nilotinib | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
